Healthcare

Viking Therapeutics is a clinical-stage biotech centered on obesity and metabolic disease, with VK2735 and VK2809 driving attention. The combination of a focused pipeline, low debt, and exposure to major healthcare markets makes its long-term outlook especially notable.

Travere Therapeutics is a rare-disease biotech increasingly shaped by FILSPARI, a kidney-disease therapy that has sharply lifted revenue and improved cash burn. The company’s progress toward commercial scale makes its transition worth a closer look.

Teleflex makes specialized medical devices used across vascular access, intervention, anesthesia, surgery, and urology. The company still has resilient hospital demand and positive cash generation, while a much lower valuation now centers the debate on whether profitability can recover.

Tango Therapeutics is building precision cancer medicines around synthetic lethality, a promising approach in oncology. Strong recent market momentum reflects rising confidence in its pipeline, while partnerships and low debt give it room to pursue high-impact clinical milestones.

Scholar Rock is a clinical-stage biotech centered on muscle-targeting medicines, with its spinal muscular atrophy program driving most of the long-term interest. The company’s appeal comes from differentiated science and a potentially meaningful role in neuromuscular care.

Sonic Healthcare runs a global diagnostics network centered on pathology testing, with recurring demand tied to everyday medical care. The analysis highlights its scale, cash generation, and discounted valuation, while examining whether margins can recover after the post-pandemic reset.

Sotera Health provides sterilization, lab testing, and cobalt-60 supply for healthcare customers. Its essential role in regulated medical workflows, strong margins, and improving operating trend make it a company worth examining closely for long-term business quality.